Yet as TRAF6 is known to play a role in other immune cells (e.g., Dendritic Cells, macrophages) and signaling pathways (e.g., NFκB activation, the PI3K cascade) with anti‐tumor potential, further study is absolutely needed to test this notion and determine the relative impact of TRAF6 targeting on Treg and effector leukocyte activity in the cancer setting. This evidence concerns the gene NFKB1 and cancer.